Patritumab Deruxtecan Demonstrated Statistically Significant ...
WEB4 days ago · The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement versus platinum plus pemetrexed induction ...
Patritumab Deruxtecan Demonstrated Statistically Significant
WEB4 days ago · Daiichi Sankyo and Merck’s patritumab deruxtecan demonstrates a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatment Discussions with global regulatory authorities to be initiated BASKING RIDGE, N.J. & RAHWAY, N.J., September 17, 2024 – The HERTHENA-Lung02 phase 3 ...
Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR …
WEB3 days ago · The investigational HER 3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) elicited a statistically significant improvement in progression-free survival (PFS) vs platinum-based ...
Patritumab Deruxtecan BLA Submission Receives Complete …
WEBJun 26, 2024 · patritumab deruxtecan in patients with EGFR-mutated locally advanced or metastatic NSCLC following disease progression with an EGFR TKI and platinum-based chemotherapy. Patients were randomized 1:1 to receive 5.6 mg/kg
Patritumab Deruxtecan Granted Priority Review in the U.S. for
WEBDec 22, 2023 · Patritumab deruxtecan was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.
WEBSep 10, 2023 · 2 trial showed that patritumab deruxtecan (HER3-DXd) demonstrated clinically meaningful and durable responses in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following disease progression with an EGFR TKI and platinum-based chemotherapy.
Patritumab deruxtecan extends PFS vs. chemotherapy in …
WEB3 days ago · Patritumab deruxtecan improved PFS compared with chemotherapy among certain patients with advanced non-small cell lung cancer, according to the agent’s manufacturer. Patritumab deruxtecan (HER3 ...
WEBMar 20, 2023 · Press Release. Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials.
Daiichi Sankyo-MSD’s ADC improves survival in NSCLC trial
WEB3 days ago · Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), met the primary endpoint of progression-free survival (PFS).. The international, multicentre, open-label trial assessed ...
Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy …
WEBDec 23, 2021 · The global, multicenter, open label, two-part phase 1 study is evaluating patritumab deruxtecan in previously treated patients with metastatic or unresectable NSCLC.
- Some results have been removed
Skip to content